Key Takeaways

• Osimert (osimertinib) is a third-generation, oral, irreversible EGFR tyrosine kinase inhibitor used to treat EGFR mutation-positive non-small cell lung cancer (NSCLC) across multiple disease stages.
• It is approved for four distinct indications: T790M mutation-positive metastatic NSCLC, first-line locally advanced or metastatic NSCLC, adjuvant treatment of early-stage EGFR-mutant NSCLC, and stage III unresectable NSCLC following chemoradiation.
• Osimertinib works by irreversibly binding the cysteine-797 residue in the EGFR kinase domain, inhibiting both sensitizing EGFR mutations and the T790M resistance mutation that limits earlier-generation EGFR-TKIs.
• Osimert is manufactured by Everest Pharmaceuticals Ltd. in Bangladesh and is available as oral tablets in two strengths — 40 mg and 80 mg.
• Key adverse effects include rash, diarrhea, nail toxicity, lymphopenia, and neutropenia, with serious risks including interstitial lung disease/pneumonitis, QTc prolongation, and cardiomyopathy requiring clinical monitoring.
• For hospital pharmacies and oncology procurement teams in Saudi Arabia and the Middle East, Osimert is a Bangladeshi-manufactured generic option accessible through Named Patient Programs, institutional tenders, and direct B2B procurement.

What Is Osimert (Osimertinib)?

Osimert (osimertinib) is a third-generation, oral, irreversible EGFR tyrosine kinase inhibitor (TKI) indicated for the treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC). It is pharmacologically distinct from first-generation reversible inhibitors such as gefitinib and erlotinib and from second-generation irreversible inhibitors such as afatinib and dacomitinib. That distinction matters clinically: osimertinib was engineered to address the resistance mechanisms that limit the durability of prior-generation agents.

Osimert is available in two oral tablet strengths — 40 mg and 80 mg — giving prescribers flexibility across treatment settings and tolerability profiles. It is manufactured by Everest Pharmaceuticals Ltd., a Bangladeshi manufacturer with established capabilities in the oncology generics segment. For procurement professionals evaluating targeted-therapy supply in the Kingdom of Saudi Arabia and the broader Middle East, Osimert represents a Bangladeshi-manufactured option within the osimertinib class.

Osimertinib’s role in EGFR-driven NSCLC is supported by an expanding body of evidence from pivotal trials including FLAURA, ADAURA, AURA3, and LAURA. For broader context, see Understanding the Role of Targeted Therapy in Cancer Treatment.

Approved Indications: What Cancer Is Osimertinib Used For?

Osimertinib is approved across four distinct clinical indications in EGFR mutation-positive NSCLC, supported by Phase III data showing meaningful improvements in progression-free and overall survival:

T790M mutation-positive metastatic NSCLC

Locally advanced or metastatic EGFR T790M mutation-positive NSCLC. T790M is the most common mechanism of acquired resistance to earlier EGFR-TKIs; osimertinib was the first agent designed to overcome it (AURA3 trial: progression-free survival 10.1 vs 4.4 months; HR 0.30).

First-line locally advanced or metastatic NSCLC

First-line treatment of tumors harboring EGFR exon 19 deletions or exon 21 (L858R) substitution mutations — the two most prevalent sensitizing EGFR mutations. The FLAURA trial established osimertinib as the preferred first-line EGFR-TKI (progression-free survival 18.9 vs 10.2 months; overall survival 38.6 vs 31.8 months).

Adjuvant treatment of early-stage EGFR-mutant NSCLC

Adjuvant therapy after complete resection in stage IB-IIIA EGFR-mutant NSCLC. The ADAURA trial showed an approximately 80% reduction in the risk of disease recurrence or death, establishing a new standard of care.

Stage III unresectable NSCLC post chemoradiation

Locally advanced, unresectable (stage III) NSCLC that has not progressed during or after platinum-based chemoradiation, in tumors with EGFR exon 19 deletions or exon 21 L858R mutations. The LAURA trial showed an 84% reduction in disease progression or death risk (HR 0.16).

Mechanism of Action: How Osimertinib Works

Osimertinib is a selective, irreversible inhibitor of the epidermal growth factor receptor. Its defining feature is the ability to inhibit both the sensitizing EGFR mutation that confers TKI sensitivity and the EGFR T790M form that drives acquired resistance to first- and second-generation agents.

Molecular Binding and Irreversible Inhibition

Irreversibility is achieved through covalent bond formation with the cysteine-797 residue in the ATP-binding pocket of the EGFR kinase domain. By forming this bond, osimertinib permanently inactivates the receptor, preventing the downstream signaling that drives tumor cell proliferation and survival. This sustained target inhibition persists beyond the drug’s plasma half-life.

Selectivity and Wild-Type EGFR Sparing

A key advantage is osimertinib’s approximately 200-fold selectivity for EGFR-activating and T790M resistance mutations over wild-type EGFR. This reduces inhibition of wild-type EGFR in normal tissue and is associated with improved tolerability, including a lower incidence of dose-limiting rash and diarrhea, compared with earlier EGFR-TKIs.

This dual-targeting capability underlies osimertinib’s effectiveness both in patients who have progressed on prior EGFR-TKI therapy due to T790M-mediated resistance and in the first-line setting. The precision of this mechanism aligns with the principles of precision medicine in oncology.

Osimert by Everest Pharmaceuticals Ltd: Product Overview

Osimert is manufactured by Everest Pharmaceuticals Ltd., a Bangladeshi manufacturer with established capabilities in oncology generics. It is available in two oral tablet strengths — 40 mg and 80 mg — giving the prescribing oncologist options suited to individual patient management and tolerability.

Formulation and Administration

Both strengths are formulated for oral administration and may be taken with or without food, supporting adherence across clinical settings. Tablets should be swallowed whole and not crushed, divided, or chewed. All administration decisions are made by the treating physician in accordance with the official prescribing information.

Manufacturer Credentials and Quality Assurance

Everest Pharmaceuticals is an established manufacturer in the generic oncology segment, with facilities adhering to Good Manufacturing Practice (GMP) standards. The availability of both 40 mg and 80 mg strengths supports dose-management flexibility as directed by the treating physician. Procurement teams sourcing Osimert for oncology units in Saudi Arabia and the wider Middle East should contact our team directly to confirm current stock availability, batch documentation, and lead times.

Regulatory Status: FDA, EMA, and Saudi Arabia Market Access

Osimertinib received initial FDA approval in November 2015 for metastatic EGFR T790M mutation-positive NSCLC, becoming the first third-generation EGFR-TKI to reach a major market. Subsequent FDA approvals expanded the indication to first-line metastatic EGFR-mutant NSCLC (April 2018), adjuvant treatment after tumor resection (December 2020), and stage III unresectable NSCLC following chemoradiation (March 2024) — each supported by positive Phase III results.

The European Medicines Agency (EMA) granted marketing authorization in December 2015, with label expansions paralleling the FDA timeline. The EMA approval is documented within the EU Risk Management Plan, confirming its regulatory standing and post-marketing surveillance across EU member states.

Market Access Pathways in Saudi Arabia

Hospital procurement of internationally approved oncology generics in KSA is frequently facilitated through Named Patient Programs (NPPs) — compassionate-use pathways for individual patients under physician supervision, particularly for medicines not yet locally registered; institutional tender mechanisms through which hospitals source medicines for their formularies; and direct hospital procurement agreements between institutions and suppliers. These pathways let oncology departments access approved therapies — including generic formulations such as Osimert — in alignment with SFDA import regulations. Procurement teams should work with their regulatory affairs departments to confirm applicable import and registration requirements for their context.

Safety Profile: Side Effects & Key Adverse Reactions

Osimertinib has a defined safety profile that oncology and procurement teams should understand when evaluating it for formulary inclusion or patient access. The data below is drawn from pooled analyses of clinical trials including FLAURA, ADAURA, AURA3, and LAURA, representing exposure across thousands of patients.

Common Adverse Reactions

The most frequently reported side effects include:

• Hematologic: Lymphopenia (63%), thrombocytopenia (51%), leukopenia (47%), and neutropenia (42%). These cytopenias are generally manageable and rarely require permanent discontinuation, though regular complete blood count monitoring is recommended.
• Dermatologic: Rash (58%), nail toxicity including paronychia (35%), and dry skin — reflecting on-target EGFR inhibition in skin and nail tissue.
• Gastrointestinal: Diarrhea (58%), nausea, decreased appetite, and constipation. The incidence and severity of diarrhea is notably lower than with first-generation EGFR-TKIs.
• Musculoskeletal: Musculoskeletal pain (36%) and back pain, typically mild to moderate.
• Respiratory: Cough (30%), which may relate to underlying lung disease rather than drug toxicity.

Drug Interactions and Metabolism

Osimertinib is metabolized primarily via CYP3A4, with contributions from CYP3A5. Concomitant use with strong CYP3A4 inducers (e.g., rifampin, phenytoin, carbamazepine, St. John’s wort) may reduce osimertinib plasma concentrations and should be avoided. Strong CYP3A4 inhibitors may increase exposure, though adjustment is generally not required. Gastric pH-altering agents may affect absorption; timing recommendations in the prescribing information should be followed.

Special Populations

Pregnancy and lactation: Osimertinib can cause fetal harm; effective contraception is advised during treatment and for a period after the final dose, and breastfeeding is not recommended during treatment. Hepatic and renal impairment: No dose adjustment is recommended for mild to moderate impairment; data in severe impairment are limited.

Important: All clinical management decisions must be made by the treating physician in accordance with the official prescribing information. Patients should consult their doctor or pharmacist before starting any medication.

Osimertinib in the Global Oncology Market: Generic Access

Osimertinib is one of the most clinically significant targeted therapies in thoracic oncology, having reshaped treatment for EGFR-mutant NSCLC. The branded originator therapy carries a very high annual acquisition cost, placing significant pressure on health systems and procurement agencies in many markets — including the Middle East — and creating access barriers where oncology budgets are constrained.

Procurement Landscape in Saudi Arabia and the Middle East

Across the Kingdom of Saudi Arabia and the wider region, oncology procurement is increasingly structured around Named Patient Programs for urgent or unregistered access, competitive institutional tender frameworks that let generic suppliers compete on quality and documentation, and direct hospital procurement agreements with established regulatory governance. These mechanisms are well-suited to sourcing internationally approved generics, where the documented regulatory standing of the reference molecule — FDA and EMA approval — supports procurement confidence.

How to Source Osimert for Your Hospital or Pharmacy

We are a Bangladeshi pharmaceutical supplier specializing in B2B oncology procurement for hospital pharmacies, institutional buyers, and distributors across the Kingdom of Saudi Arabia and the broader Middle East. We supply Osimert — osimertinib 40 mg and 80 mg oral tablets — manufactured by Everest Pharmaceuticals, giving healthcare institutions access to quality-assured generic osimertinib through established international channels.

Documentation and Regulatory Support

We facilitate international procurement inquiries and can provide product availability and lead-time estimates, Certificate of Analysis (CoA) and batch documentation, manufacturing licenses and GMP certificates, product specifications and stability data, documentation support relevant to KSA import requirements and SFDA pathways, and commercial and shipping documentation. The process is straightforward: contact our team with your requirements, we confirm current stock and lead times for both 40 mg and 80 mg strengths, provide the requested documentation for your evaluation, and prepare a formal quotation before coordinating international shipping and post-delivery support.

Our specialized oncology focus covers cold-chain management, documentation standards, and regulatory pathways, backed by established relationships with institutions across Saudi Arabia and the Gulf and flexible models for Named Patient Programs, institutional tenders, and ongoing supply agreements.

To inquire about current availability of Osimert 40 mg or 80 mg, lead times, and procurement terms, please contact our team directly. We do not publish pricing publicly — all pricing and availability is provided through direct B2B inquiry tailored to your institution’s requirements. Please consult a qualified physician or healthcare professional for clinical decisions.